- Previous Close
19.59 - Open
19.80 - Bid --
- Ask --
- Day's Range
19.75 - 19.91 - 52 Week Range
16.08 - 23.50 - Volume
706 - Avg. Volume
87 - Market Cap (intraday)
38.187B - Beta (5Y Monthly) --
- PE Ratio (TTM)
40.30 - EPS (TTM)
0.49 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield 0.78 (3.71%)
- Ex-Dividend Date Feb 12, 2025
- 1y Target Est
--
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
www.kenvue.com22,000
Full Time Employees
December 29
Fiscal Year Ends
Sector
Industry
Recent News: J4D.F
View MorePerformance Overview: J4D.F
Trailing total returns as of 4/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: J4D.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: J4D.F
View MoreValuation Measures
Market Cap
37.89B
Enterprise Value
44.85B
Trailing P/E
39.85
Forward P/E
18.73
PEG Ratio (5yr expected)
2.20
Price/Sales (ttm)
2.68
Price/Book (mrq)
4.25
Enterprise Value/Revenue
3.19
Enterprise Value/EBITDA
19.96
Financial Highlights
Profitability and Income Statement
Profit Margin
6.67%
Return on Assets (ttm)
6.88%
Return on Equity (ttm)
9.87%
Revenue (ttm)
15.45B
Net Income Avi to Common (ttm)
1.03B
Diluted EPS (ttm)
0.49
Balance Sheet and Cash Flow
Total Cash (mrq)
1.07B
Total Debt/Equity (mrq)
90.18%
Levered Free Cash Flow (ttm)
1.62B